相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study
C. Warren Olanow et al.
JOURNAL OF PARKINSONS DISEASE (2021)
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
C. Warren Olanow et al.
LANCET NEUROLOGY (2020)
Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
Donald G. Grosset et al.
PARKINSONISM & RELATED DISORDERS (2020)
Clinical Trial Highlights - Infusion Therapies
Neha Prakash et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions
J. J. Ferreira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebocontrolled phase 3 trial (vol 18, pg 145, 2019)
P. A. LeWitt et al.
LANCET NEUROLOGY (2019)
Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations
Nishit B. Modi et al.
CLINICAL NEUROPHARMACOLOGY (2019)
Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations
Federico Carbone et al.
CNS DRUGS (2019)
Safety Profile of Opicapone in the Management of Parkinson's Disease
Andrew Lees et al.
JOURNAL OF PARKINSONS DISEASE (2019)
Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
Nishit B. Modi et al.
CLINICAL NEUROPHARMACOLOGY (2019)
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
Peter A. LeWitt et al.
LANCET NEUROLOGY (2019)
ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability
Yuval Ramot et al.
CNS DRUGS (2018)
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
Regina Katzenschlager et al.
LANCET NEUROLOGY (2018)
Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence
Sagari Bette et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System
Amnon C. Sintov et al.
PHARMACEUTICAL RESEARCH (2017)
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations A Randomized Clinical Trial
Anthony H. V. Schapira et al.
JAMA NEUROLOGY (2017)
for the LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (vol 13, pg 141, 2014)
C. W. Olen et al.
LANCET NEUROLOGY (2014)
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
C. Warren Olanow et al.
LANCET NEUROLOGY (2014)
Pathophysiology of the basal ganglia in Parkinson's disease
JA Obeso et al.
TRENDS IN NEUROSCIENCES (2000)
分享论文
